Predicta Biosciences is a precision oncology company that builds a molecular insights platform for blood cancer care. By utilizing a single blood sample, the company integrates multiomics and liquid biopsies to generate longitudinal genomic and immune insights for diagnostics.
Subscribe to see Predicta, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Predicta, Inc. is a biotech, life sciences & techbio company headquartered in Mcminnville, United States. It has raised at least $1.4M across the 3 funding rounds on record. Its most recent funding round raised $135,000 in February 2020. Xcout tracks 12 named people at Predicta, Inc., including Brian McKernan (CEO).
As of 16 November 2026. Source: Xcout Intel.
6 more named people on record for Predicta, Inc., with roles, board committees and tenure — see the full roster →
At least $1.4M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $135,000 | — | |
| Seed | $175,000 | — | |
| SEC Form D filing | $1.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Predicta, Inc.'s closest competitors — see the full list of competitors and alternatives →
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
OncoHost is an Israeli precision-oncology biotechnology company that develops blood-based proteomic tests and computational analytics to characterize cancer patients and predict responses to immunotherapy. Its products are intended to help oncologists personalize treatment decisions and identify mechanisms of resistance, serving cancer patients, clinicians, pharmaceutical companies, and researchers.
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions and liquid biopsy cancer diagnostics. Founded in 2012 and based in Kirkland, United States, the company was acquired by Agilent Technologies.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Predicta, Inc.? Suggest a correction · Work at Predicta, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.